Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Highly Accessed Debate

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

Magnus Gisslén1*, Richard W Price2 and Staffan Nilsson3

Author Affiliations

1 Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg, Sweden

2 Department of Neurology, University of California San Francisco, San Francisco, CA, USA

3 Department of Mathematical Statistics, Chalmers University of Technology, Gothenburg, Sweden

For all author emails, please log on.

BMC Infectious Diseases 2011, 11:356  doi:10.1186/1471-2334-11-356

Published: 28 December 2011

Abstract

Background

A substantial prevalence of mild neurocognitive disorders has been reported in HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI).

Discussion

ANI is identified by performance on formal neuropsychological testing that is at least 1 SD below the mean of normative scores in at least two cognitive domains out of at least five examined in patients without associated symptoms or evident functional impairment in daily living. While two tests are recommended to assess each domain, only one is required to fulfill this diagnostic criterion. Unfortunately, this definition necessitates that about 20% of the cognitively normal HIV-infected population is classified as suffering ANI. This liberal definition raises important ethical concerns and has as well diagnostic and therapeutic implications. Since neither its biological substrate, prognostic significance nor therapeutic implications are clearly established, we recommend that this diagnosis be modified or applied cautiously.

Summary

The diagnoses of less severe forms of neurocognitive disorders in HIV relies on the outcomes of neuropsychological testing, and a high proportion of HIV-infected patients with effective cART may be classified as neurocognitively abnormal using the current criteria. The definition of ANI is not stringent, and results in approximately 20% of the population being classified as abnormal. To us this seems an unacceptable false-positive rate.

Please see related article: http://www.biomedcentral.com/1741-7015/9/138 webcite